Combination of low-dosage cyclosporine and topical pimecrolimus in severe atopic dermatitis with chronic hepatitis B.

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Acta Dermato-Venereologica

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.2340/00015555-0327PMID 18176762
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Update on the use of ciclosporin in immune‐mediated dermatoses

  2006cited by this paper
• Inhibitory effect of cyclosporine A on hepatitis B virus replication in vitro and its possible mechanisms.

  2005cited by this paper
• Pimecrolimus leads to an apoptosis-induced depletion of T cells but not Langerhans cells in patients with atopic dermatitis.

  2005cited by this paper
• New insights into atopic dermatitis.

  2004cited by this paper
• Percutaneous absorption of drugs used in atopic eczema: pimecrolimus permeates less through skin than corticosteroids and tacrolimus.

  2004cited by this paper
• Pimecrolimus does not affect Langerhans cells in murine epidermis

  2003cited by this paper
• Actigraphy assessment of sleep disturbance in patients with atopic dermatitis: an objective life quality measure.

  2003cited by this paper
• Combined interferon alpha2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial.

  2003cited by this paper
• Combined interferon α2b and cyclosporin A in the treatment of chronic hepatitis C: controlled trial

  2003cited by this paper
• Actigraphy assessment of sleep disturbance in patients with atopic dermatitis: An objective life quality measure

  2003cited by this paper
• Natural Killer T Cell Activation Inhibits Hepatitis B Virus Replication in Vivo

  2000cited by this paper
• A novel anti‐inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: in vitro pharmacology

  1999cited by this paper
• Ascomycin macrolactam derivative SDZ ASM 981 inhibits the release of granule-associated mediators and of newly synthesized cytokines in RBL 2H3 mast cells in an immunophilin-dependent manner

  1998cited by this paper
• Treatment of acute severe exacerbation of chronic hepatitis B with cyclosporin A and interferon-beta: a case report.

  1995cited by this paper

• Systemic Therapy for Atopic Dermatitis in Older Adults and Adults With Comorbidities: A Scoping Review and International Eczema Council Survey

  2022cites this paper
• British Association of Dermatologists guidelines for the safe and effective prescribing of oral ciclosporin in dermatology 2018

  2019cites this paper
• Immunosuppressive treatment combined with nucleoside analog is superior to nucleoside analog only in the treatment of severe thrombocytopenia in patients with cirrhosis associated with hepatitis B in China: A multicenter, observational study

  2015cites this paper
• Mechanism underlying the effect of combined therapy using glucosamine and low-dose cyclosporine A on the development of atopic dermatitis-like skin lesions in NC/Nga mice.

  2013cites this paper
• Novel and recurrent ALDH3A2 mutations in Italian patients with Sjögren-Larsson syndrome

  2007cites this paper